A specific antiserum for morphine-6-glucuronide (M6G) has been raised in a rabbit in response to immunization with a novel hapten: protein conjugate (N-aminobutylnormorphine-6-glucuronide-thyroglobulin). Cross-reactivity with morphine and structurally related compounds was found to be negligible as expected from the nature of this immunogen. Using this antiserum, a simple, rapid and robust radioimmunoassay (RIA) has been developed for determination of M6G in samples of human plasma. The assay has a sensitivity of 0·05 ng/mL using 100J.LL sample volumes and affords complete recovery of M6G over the range 2-200 ng/mL. The presence of morphine or morphine-3-glucuronide at concentrations up to 100 times the levels of M6G did not result in any measurable interference. Close agreement was obtained between M6G results obtained using the RIA and a specific high-performance liquid chromatography assay. This RIA offers an attractive alternative to existing methods for the determination of M6G in human plasma and will facilitate further metabolic and pharmacokinetic studies of morphine and M6G in the clinical setting.
SUMMARY. A specific antiserum for morphine-6-glucuronide (M6G) has been raised in a rabbit in response to immunization with a novel hapten: protein conjugate (N-aminobutylnormorphine-6-glucuronide-thyroglobulin). Cross-reactivity with morphine and structurally related compounds was found to be negligible as expected from the nature of this immunogen. Using this antiserum, a simple, rapid and robust radioimmunoassay (RIA) has been developed for determination of M6G in samples of human plasma. The assay has a sensitivity of 0·05 ng/mL using 100J.LL sample volumes and affords complete recovery of M6G over the range 2-200 ng/mL. The presence of morphine or morphine-3-glucuronide at concentrations up to 100 times the levels of M6G did not result in any measurable interference. Close agreement was obtained between M6G results obtained using the RIA and a specific high-performance liquid chromatography assay. This RIA offers an attractive alternative to existing methods for the determination of M6G in human plasma and will facilitate further metabolic and pharmacokinetic studies of morphine and M6G in the clinical setting.
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It is now well recognized that morphine-6glucuronide (M6G) is an important metabolite of morphine and makes a significant contribution to the analgesic activity usually attributed to the parent compound. Although the major metabolite of morphine, morphine-3-glucuronide (M3G), is pharmacologically inactive, it was demonstrated some twenty years ago that M6G is 20-45 times more analgesic, with a longer duration of action, than morphine itself after intracerebroventricular administration.' More recently, the analgesic activity of M6G has also been demonstrated in man? and significant quantities of this metabolite have been found following both acute and chronic administration of morphine. Indeed, the ratio of the area under the plasma concentration versus time curves for morphine, M3G and M6G after oral morphine administration is approximately 1; 10 : 50, respectively. 3, 4 M6G has also been detected in the cerebrospinal fluid of patients dosed with morphine via both the parenteral" and ora1 6 ,7 routes.
Methods for the determination of morphine and its glucuronide metabolites have generally involved the use of high-performance liquid chromatography (HPLC)8,9 or radioimmunoassay (RIA). 10,1 I The HPLC assays are sensitive and specific, and allow simultaneous quantitation of morphine and its metabolites. However, attempts to introduce these assays into routine use have encountered a number of problems arising from the labour-intensive sample preparation and detection techniques required to obtain such low limits of quantitation. A differential RIA procedure has been described for the determination of morphine and M6G in plasma samples.'? This method has recently been modified in our Iabcratoryt'! and involves the determination of M6G levels by subtracting results obtained with an antiserum produced in response to an N-succinylnormorphine-BSA immunogen, which specifically measures morphine in the presence of its metabolites, from results obtained with a non-specific antiserum (produced in response to a 6-succinylmorphine-BSA immunogen) which is not able to distinguish between morphine and M6G. Although this approach has found some success, the major drawback is the interference with the non-specific antiserum from high levels of M3G which may be circulating in the plasma following chronic oral administration of morphine. Thus, there is still a need for a reliable, sensitive and specific method for the determination of M6G in biological fluids. This has become more of a problem since the importance of M6G as a morphine metabolite and as a potential analgesic in its own right have become evident. Indeed, it has recently been recommended that M6G be routinely monitored following morphine administration if a reliable interpretation of the relationship between the pharmacokinetics and the pharmacodynamics of analgesia is required." This report describes the production of a specific M6G antiserum and its subsequent use in the development of a direct, sensitive RIA for the determination of MOOin human plasma samples.
MATERIALS AND METHODS

Chemicals
Morphine alkaloid and other opioid standards were purchased from MacFarlan Smith Ltd (Edinburgh, UK). Morphine-3, {j-D-glucuronide was purchased from Sigma Chemical Co. Ltd (Poole, UK) and morphine-6,{j-D-glucuronide from Salford Ultrafine Chemicals Ltd (Manchester, UK). Morphine-3,6-diglucuronide (M-3,6-diG) and the N-aminobutylnormorphine-6-glucuronide (N-ABNG) hapten were both synthesized by Dr F Schein mann (Salford Ultrafine Chemicals Ltd). Dextran T-70 was obtained from Pharmacia/ LKB (Milton Keynes, UK). Activated charcoal (Norit A), lodo-Gen (I,3,4,6-tetrachloro-3,6diphenylglycouril), bovine thyroglobulin and glutaraldehyde were all supplied by Sigma Chemical Co. Ltd. Na [ 1251] was supplied by ICN Flow Laboratories (High Wycombe, UK). All other RIA reagents were of analytical grade and were purchased from BDH Chemicals Ltd (Poole, UK). Non-ulcerative Freund's adjuvant (NUFA) was supplied by Guildhay Antisera Ltd (Guildford, UK).
The assay buffer for the RIA was a 0·05 M phosphate buffer, pH 7· 4, containing 6· 0 g sodium chloride, 1·0 g gelatin, and 13·0 mg thiomersal per litre of distilled water. The charcoal suspension contained 10 g of Norit A and 1 g Ann Clin Biochem 1995: 32 Dextran T-70 per 400 mL 0·05 M phosphate buffer, pH 7·4. A stock standard of M6G was prepared as 1 mg/mL in distilled water. This was then diluted 1: 1000 in assay buffer and stored in 100 ILL aliquots at -20°C for up to 2 months.
PREPARATION OF PZSI]-M6G
The stages involved in the preparation and purification of [ 1251 ]-M6G were as described previously!' and were based on the method described for the radioiodination of morphine. 12 For use in this assay, the radiolabel was diluted in assay buffer to give approximately 8000 cpm/IOO ILL fresh radiolabel.
Preparation of N.ABNG-thyrog1obulin conjugate
The N-ABNG hapten was coupled to bovine thyroglobulin by means of the glutaraldehyde condensation reaction using a molar ratio of 200: 1 for protein: hapten as follows: 10 mg of N-ABNG hapten was dissolved in 2· 5 mL 0·2 M borate buffer pH 8· 2 containing 20 ILL 25070 glutaraldehyde. This mixture was stirred for 15 min at room temperature. Then 35 mg of porcine thyroglobulin were added and the mixture was stirred gently overnight at room temperature. The resulting conjugate was then dialysed against two changes of distilled water (2 X 500 mL) over 48 h and stored at 4°C following the addition of 0·1 % sodium azide.
Immunization protocol
The above conjugate was diluted with distilled water to provide an immunogen with a final protein concentration of 5 mg/mL. A New Zealand White rabbit (R29) was challenged with 2·5 mg of this immunogen in 0·5 mL 0·9% saline and 100 ILL Bacille-Calmette-Guerin (BCG) vaccine emulsified with 1 mL NUFA at six intramuscular sites. Booster injections were administered when the response following the previous immunization had plateaued and consisted of 1· 25 mg immunogen emulsified as before without the addition of BCG. Blood was obtained from the marginal ear vein at approximately 2 week intervals following each immunization and the resulting serum stored at 4°C following the addition of O' 1% sodium azide.
RIA procedure
The procedure adopted for use with [ 1251 ]-M6G radiolabel was as described previously. II Comparison of HPLC and RIA results forM6G A selection of 36 plasma samples were obtained from healthy volunteers recruited at the Department of Medical Oncology, Hornerton Hospital, London, UK. These subjects had received a single dose of M6G (1 mg170 kg) as an I.V. bolus and plasma MOOlevelshad previously been determined using a specific HPLC method." These results were compared to those obtained using this RIA.
Antiserum specificity
The cross-reactivity profile for the antiserum used in this assay was assessed by comparing the ability of a range of structurally related analogues to displace 50% antibody-bound radiolabel using the accepted procedure. 12 Antibody production The immune response of rabbit R29 obtained following the administration of the N-ABNGthyroglobulin conjugate is shown in Fig. 1 . The bleed taken 2 weeks after the second booster injection was chosen for further assay development and was used at a titre of 1/5000.
RIA performance
Using the antiserum at a titre of 1/5000 and [ 1251] -M6G at a dilution of 115000, the inter-assay variation (mean and SO) for each concentration point (between 0 "125-7" 0 ng/mL) for five individual calibration curves is shown in Fig. 2 . The B o value was 25·7% of the total 4 FIGURE I. Immune response to injection of N-aminobutylnormorphine-6-glucuronide-thyroglobulin in one rabbit. (Bleed X was used for assay development.) Prime Boost §3 l suitably diluted was incubated with 100ilL diluted antiserum and 100 ilL radiolabel for 1 h at 4°C. Phase separation was subsequently achieved by the addition of 100 JLL charcoal suspension followed by centrifugation. The resulting supernatant was aspirated and the charcoal pellet was counted for 100 s in a 12-channel Multigamma II counter (LKB, Milton Keynes, UK). Percentage binding was calculated for each standard and sample, and data reduction was carried out using a smoothed spline plot and the results calculated by interpolation.
Assessment of antibody binding characteristics
The ability of each bleed from rabbit R29 to bind [ 1251] -M6G was investigated by incubating increasing dilutions of antiserum with the radiolabel for 1 h at 4°C. Separation of the bound and free phases was then achieved using dextran-coated charcoal and the free fraction in the charcoal pellet was counted for 120s in an LKB multigamma counter. The initial antiserum dilution (that which gave rise to 50070 binding of [ 1251] -M6G at zero dose) was determined by plotting percentage bound of total counts added against the reciprocal of the antiserum dilution. This dilution was chosen as the antiserum titre for subsequent use in the assay.
Assay calibration and validation
Calibration curves were prepared in assay buffer by spiking M6G over the range from 0'125-7 ng/mL. The optimum calibration curve with respect to assay sensitivity was determined by processing a number of curves using the antiserum titre determined in the previous section and dilutions of radiolabel ranging from 1/4000-1/8000. Theoretical assay sensitivity was defined as being two standard deviations (SO) from the mean of 20 replicate tests of the zero standard. Intra-and inter-assay variation were assessed by the repeat analysis of a plasma pool prepared using samples obtained from patients dosed with oral morphine. In addition, a range of dilutions of this plasma pool were assayed in order to assess the degree of parallelism for this assay. Accuracy was assessed by determining the recovery of M6G from control plasma spiked with artificial mixtures of M6G, morphine and/or M3G at levels that might be experienced clinically. Percentage recoveries for M6G were calculated by dividing the actual result by the expected result. counts. The overall mean coefficient of variation (CV) for this calibration range was less than 100/0 over the linear portion of the curve (0·125-2·5 ng/mL). Non-specific binding was always < 60/0 total binding, and the theoretical assay sensitivity was calculated to be 0·05 ng/mL (this value also represented approximately a 2 SD decrease in binding from zero). Repeat analysis of a plasma pool diluted over the range 11200 to 1/800 in assay buffer indicated an intra-assay CV of 80/0 (mean 656·6 ng/mL, SD 58·2 ng/mL, n = 6) and an inter-assay CV of 7· 1% (mean 626·6ng/mL, SD 44·4ng/mL, n=6). In addition, the data displayed in Fig. 3 Antiserum specificity Setting the reactivity of this antiserum for M6G at 100%, the cross-reactivity of this bleed of antiserum with a range of structural analogues (morphine, M3G, M-3,6-diG, normorphine, codeine, diamorphine) was found to be negligible «0·01%), as shown in Fig. 4 . Table 1 shows the recovery of M6G from control human plasma both alone and in the presence of increasing concentrations of morphine or M3G. It can be seen that recovery was complete over the concentration range studied and was not affected by the presence of morphine or M3G.
Analytical recovery
Comparison of HPLC and RIA results for M6G A significant correlation was evident between results obtained using these two methods (r = 0·985; n = 36). Linear regression analysis of the data gave the equation y = 1· 39x + 2·49 (where y= RIA; X= HPLC).
DISCUSSION
The initial objective of this study was to select and synthesize a hapten suitable for raising a specific M6G antiserum. Previous studies had described the successful production of specific antisera to morphine using derivatives of the parent compound modified at either the 2-position 1J"'loong/mL M6G.
(on the phenolic ring) or the cyclic N-position.IO.1 4 It was therefore decided to prepare derivatives of M6G modified in a similar manner. Unfortunately, attempts to prepare a 2-substituted M6G hapten met with limited success, largely due to the instability of the product and some of the reactive intermediates. The substitution of an aminobutyl side-chain onto the cyclic N-position of the molecule proved more successful, and this hapten was subsequently linked to thyroglobulin to prepare a suitable immunogen. The immunization of one rabbit quickly gave rise to antibodies which were able to bind [ 12SI] -M6G. The immune response increased following each boost but the largest rise in titre was observed when injections were administered 22-38 weeks apart, i.e. when titres had been allowed to fall and reach a low plateau. After this large rise in titre, a large bleed was collected and the serum harvested was subjected to further characterization. The M6G standard curve was optimized by following the recommended procedure involving the incubation of antiserum diluted to the required titre with a range of dilutions of radiolabel." Once these factors had been determined, the performance of the RIA over the range of the curve (0'125-7 ng/mL) was excellent, with an inter-assay CV < 100/0 over the linear portion (0,125-2'5 ng/mL). In addition, excellent assay reproducibility was achieved following the repeat analysis of a pooled plasma sample, and the recovery of M6G from spiked control plasma was complete over the range 2-200 ng/mL. In our earlier report, a thorough investigation of an antiserum's specificity profile was found to be necessary when large quantities of circulating metabolites were expected. I I Thus, in addition to employing the accepted criteria for cross-reactivity assessment, recovery of M6G from a range of artificially spiked plasma samples containing M6G in the presence of morphine or M3G was determined. These investigations have shown that antiserum R29 exhibits a high degree of specificity towards M6G and negligible interference from the structurally related analogues investigated is apparent. In addition, accurate recovery of M6G from spiked plasma samples is obtained with this assay even in the presence of significant quantities of morphine and M3G. These findings are in accordance with the proposed principle that, following immunization with a hapten-protein conjugate, the resulting antibodies generally recognize the region of the hapten that is furthest removed from the point of linkage to the protein and this fact determines their specificity. 16 From these results, it would appear that the 6-glucuronide moiety serves as the antigenic determinant and it was interesting, therefore, to observe negligible interference from M-3,6-diG. This finding is sigificant as, although M3G and morphine have not been detected following the intravenous administration of M6G,2 the metabolic fate of morphine would suggest that M-3,6-diG is a possible metabolite of M6G. At present, information on the metabolic fate of M6G is scarce, but if M-3,6-diG were found to be an important metabolite then further recovery studies of M6G in the presence of increasing concentrations of M-3,6-diG would be required. It is possible that other 6-conjugated metabolites e.g. codeine-6-glucuronide and morphine-6sulphate may cross-react to some extent with this antibody, but the extent to which codeine and hence codeine-6-glucuronide are formed following morphine administration is still a matter of some debate.'? In any event, significant quantities of these compounds would not be expected and any interference experienced is likely to be minimal.
Wherever possible, the final stage in the validation of any biological assay should involve a correlation with an established chromatographic assay. In general, M6G results for a selection of clinical samples obtained using the RIA demonstrated close agreement with those obtained by HPLC. However, the RIA was found to give rise to slightly elevated levels of M6G at higher concentrations. One possible explanation for these differences is interference from high levels of circulating metabolite(s), but the data already discussed in this report has provided strong evidence to support the absolute specificity of this antiserum for M6G and this explanation must therefore be considered unlikely. Further studies are required to investigate the nature of the discrepancy between the HPLC and RIA results using samples obtained from patients receiving morphine and/or M6G administered by both the intravenous and oral routes. CONCLUSION This report has described the production of a specific antiserum for M6G and its subsequent use in a direct, sensitive RIA for the determination of this compound in samples of human plasma. An advantage of the assay over existing methods is its potential for high sample throughput with a small sample volume in the absence of any sample pre-treatment and it represents an attractive alternative to other methods currently available for monitoring plasma levels of M6G in clinical studies investigating the pharmacokinetics of morphine and M6G.
